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The present dissertation provides an overview of relevant marketing topics as targeting, 
competitive advantage and its influence in the firm’s ability to outperform its 
competitors through analyzing the case study of PharmAssistant, a Portuguese startup 
that is developing patient engagement solutions to undermine the non-adherence to 
complex medication regimes. The company developed a smart pill dispenser and a 
mobile app, thus operating in the digital health market, and now the CEO is having 
doubts deciding the most efficient path to commercialize its products: should we 
continue targeting patient with at least one chronic disease or should we target business 
that can benefit in selling the products.  The dissertation uses marketing research to 
collect information about the company, market, consumers and competitors. Hence, the 
implications of the findings for the selection of the most desirable target are discuss.  
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A presente dissertação oferece uma visão geral de tópicos relevantes de marketing como 
targeting, vantagem competitiva e a sua influência na capacidade de uma empresa 
superar os seus competidores através da análise do caso de estudo da PharmAssistant, 
uma startup portuguesa que está a desenvolver soluções que envolvam o paciente, para 
debilitar a não adesão a regimes complexos de medicação. A empresa desenvolveu uma 
caixa de comprimidos inteligente e uma aplicação de telemóvel, deste modo opera no 
mercado de saúde digital. Actualmente o CEO apresenta dúvidas para decidir qual o 
caminho mais eficiente para comercializar os seus produtos: devemos continuar a ter 
como alvo pacientes com no mínimo uma doença crónica ou devemos ter como alvo 
empresas que beneficiem com a venda dos produtos. A dissertação usa pesquisas de 
mercado para recolher informação sobre a empresa, o mercados, os consumidores e os 
competidores. Consequentemente, as implicações dos resultados para a escolha do alvo 
mais desejável são discutidas. 
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1.1. Problem statement   
PharmAssistant is a Portuguese startup created in 2014 that focus in creating a patient 
engagement solution in the US digital health market. It developed two products, a smart 
pill dispenser and a mobile app that aim to undermine patient’s adherence to complex 
medication regimes. The company growth is parallel to the evolution of the knowledge 
of its consumers and the team doubts the initial path designed for the company 
regarding the consumer targeting is the most efficient.  
This dissertation revolves around the company’s main dilemma: will PharmAssistant 
follow a more effective path inside the operating market if it change its current 
target? 
In order to address the problem stated before, that surfaced due to the owner conviction 
that 2 years after its foundation the company is facing a crucial time to set a clear path 
in order to create a sustainable position in the digital health market, the three research 
question uncover in the next section were develop. 
 
1.2. Research Questions  
RQ1: What forces influence a firm’s sustainability in the digital health market? 
RQ2: What is the most desirable target for PharmAssistant? 
RQ3: What measures can PharmAssistant adopt to better meet the needs of its desirable 
target?   
 
1.3. Methodology 
This dissertation combines exploratory and descriptive research methods to address the 
three research questions, in an attempt to solve the main problem. I have collect 
secondary data to have information regarding the digital health market and after analyze 
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it in order to understand and characterize the main forces that influence the market and 
the existing degree of competition.  
To understand the US market consumers and highlight the main factors contributing for 
their behavior adding to secondary data collected in the internet and in the company, 
interviews with the PharmAssistant’s most relevant members in terms of consumer 
knowledge were made. In order to grasp the firm’s current positioning and the possible 
paths for the future, an interview with the CEO was conducted. The purpose of the 
research conducted was not only to solve the firm’s dilemma but also to create a more 
engaging and solid case study. 
 
1.4. Relevance to research 
This dissertation adds to the existing literature in a managerial standpoint. The 
document summarizes the existing research on the topics of targeting and competitive 
advantage, through presenting in the literature review the main approaches academics 
defend regarding these topics. Furthermore, it serves as an example how a startup 
should use the lens of the academic research in order to envision and construct a 
sustainable positioning in the market without losing focus on its target consumer.    
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2. Literature Review 
This sections intends to establish a theoretical overview of some relevant academic 
studies, models and cases on topics related to targeting, segmentation and sources of 
competitive advantage. According to several authors, with exception of competitive 
advantage, academics do not seem to have made significant efforts to expand and 
develop the original thinking on the previous topics. Therefore, most of the articles cited 
in the present section are not very recent. Despite, an attempt was made to include only 
articles that are current and insightful for the discussion trigger by the dissertation. 
2.1. Segmentation and Targeting 
Market segmentation has been a highly comment topic among the academic 
community. It is one of the most useful concepts in marketing and numerous bases for 
segmenting a market with their own set of advantages and disadvantages have been 
propose (Wind, 1978), from discriminant analysis, canonical analysis, factor analysis, 
cluster analysis to multidimensional scaling. Dickson and Ginter (1987) based on the 
theoretical economic work of Chamberlin (1965), Rosen (1974) and Lancaster (1979) 
defined marketing segmentation as “heterogeneity in demand functions exists such that 
market demand can be disaggregated into segments with distinct demand function”. 
Nevertheless, as Blattberg et al, (1978) pointed out the concept practical relevance for 
managers is related to the segmentation’s ability to divide consumers in homogeneous 
groups that differ substantially in purchase behavior.  According to Percy (1976), for an 
effective marketing segmentation the firm cannot study the brand or product, rather it 
should study the environment the product is used and the consumer attitudes towards 
this environment. Hence, “the study will be concerned with the situational context of 
use, not the product itself. This understanding of the environment permits a broader 
development and evaluation of strategic alternatives.”  
Greengrove (2002) defended that segmentation could be done following two main 
approaches: needs based segmentation that uses as dividing factor the customer needs 
and characteristics based segmentation that uses as dividing factor the customer 
characteristics, attitudes or behavior. Dibb and Simkin (2009) citing Weinstein (2004) 
mentioned that “although the benefits of segmentation are now widely acknowledged, 
these must be weighed against the resource implications associated with implementing 
segmentation in practice”. The authors went further through identifying, with base in 
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the published material on the topic of segmentation, a mix of barriers that undermine the 
firm’s ability to implement an effective segmentation. An overview of those barriers 
were categorized in the form of the following table 1.  
  
Nevertheless, the authors ended by acknowledging that “applied studies are urgently 
need” to close the gap between theoretical and practical application of marketing 
segmentation.  In their book, Armstrong, Kotler, Saunders and Wong (1999) define 
targeting as “the process of evaluating each market segment’s attractiveness and 
selecting one or more segments to enter. As mentioned by Percy (1976), “although 
many consumers may be considered potential consumers, some are better prospects than 
other”. 
Concluding, citing Greengrove (2002) is clear that the “successful brand development 
(aka “marketing”) depends on a solid understanding of marketing segmentation. Many 
would say that effective strategic segmentation lies at the heart of the strategic 
marketing process.”.  
 
2.2. Competitive Advantage   
As stated by several academics the concept of competitive advantage has been widely 
discussed. This concept is particularly discussed by industrial organization (IO) 
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economist and proponents of the resource-based view model of the firm (RBV). 
Competitive advantage is attain when a firm is able to outperform its competitors. 
Regarding the sources contributing for that occurrence authors defend two possible 
approaches. Dyerson et al, (2015)  based on the research of Caves and Porter (1977), 
Rumelt (1991), Barney (1991), mentioned that the IO economists defend that 
competitive advantages are determine by “an exogenous force from the market position 
in an industry”; alternatively RBV researchers defend that competitive advantage is 
determine by “endogenous force from resources and capabilities”. One of the most 
influent authors for IO economists is Michael Porter. According to Porter (1980, 1985) 
firms operate in the same industry if they produce close substitutes. The author goes 
further by stating that five structural forces (threats from potential entrants, supplier 
power, buyer power, substitute products and internal rivalry) determine the industry’s 
overall competiveness and profitability. The author also points out that a firm can 
positioning itself against the pressure of these forces and erect entry barriers for 
potential competitors following one of the so-called generic competitive strategies, 
regardless of its business. Thus, a firm can exploit its positioning in an industry to create 
competitive advantage through following a “differentiation”, “cost leadership” or 
“focus” strategy. Cost leadership is obtain through offering the products at the lowest 
cost in the digital health market and focus by targeting on a narrow target with 
specialized needs. While the definition of cost leadership and focus is consensual the 
definition of differentiation is more ambiguous. Dickson and Ginter (1987) citing one of 
the pioneers of marketing, Shaw (1912) described differentiation “as meeting human 
wants more accurately than the competitors”. For the authors the result is a “buildup 
demand” for the producer’s product and a potential for a price level higher than that of 
the existing stock commodity. Chamberland (1965) and Porter (1976) stated that 
product differentiation is based on physical and ono-physical product differences. As 
concluded by Dickson and Ginter (1987) the two authors defend the definition of 
product differentiation as “the degree of cross-price inelasticity with respect to 
competing brands”. Contradicting, Galbraith (1967) and Samuelson (1976) defended 
that most product differentiation is “artificial” and is achieved by advertising and 
promotions that influence consumers’ demands. For RBV proponents the firms’ ability 
to outperform competitors comes from possessing resources with four attributes: 
valuable, that explores opportunities and threats; rare, that are unique among actual and 
future competition; imitable and non-substitute, which cannot have other products that 
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are perceived as similar. Summarizing, according to the two accepted approaches a firm 
outperform its competitors due to a strong market position (Porter, 1980) or from 
acquiring valuable, rare, imitable and non-substitute resources (Barney, 1991). Several 
researchers studied the topic of competitive advantage. However, only a few look into 
the difference between temporary competitive advantage (TCA) and sustainable 
competitive advantage (SCA) (Dyerson et al, 2015). According to Barney (1991) the 
difference between the two topics lays in the firms’ ability to achieve an un-duplicated 
competitive advantage, if the firms attains such positioning than the competitive 
advantage is sustained. The author also adds that to be sustained the advantage does not 
need to last forever, changes in the economic structure of an industry may upset the 
competitive advantage. For Bowman and Ambrosini (2000) the difference between 
TCA and SCA builds in value creation or value capture. For D’Aveni et al, (2010) SCA 
can be made up of a series of temporary advantages over time. Dyerson et al, (2015) 
integrated both IO and RBV perspectives and suggested that through superior market 
position firms can achieve TCA and temporary competitive advantages is the base for a 
firm improvement of its resources and capabilities in order to achieve a SCA. 
Nowadays several markets are continuously affected by trends and technologic shocks. 
In order to sustain competitive advantages in such disruptive environments firms must 
constantly transform and innovate to acquire and develop valuable and rare resources 




3. Case study: “The optimal consumer: 
Targeting the right consumers to meet 
PharmAssistant’s strategic goals” 
 
Diogo Ortega is waiting in a boarding gate of Schönefeld Airport (SXF), in Berlin for 
his flight back to Lisbon. He cannot fully believe and apprehend the path he, and his 
team, made in the last couple of years. Primarily, the exponential growth in terms of 
knowledge that progressed the last 4 months in Berlin under the Bayer’s Grants4Apps 
acceleration program1. The feedback they received from investors in their final pitch 
keeps ramble in his mind.  
“First, let me congratulate all of you for the presentation and the idea (…) I’m 
not really sure you are addressing this market in the most efficient way. You are 
placing all of your efforts in selling these products to the final consumer. 
However that might not be the most efficient way (...)”      
This issue was not a surprise for the team. Since the early stages of the company 
survival Diogo had suspicions they were not following the most efficient path to raise 
the quality of healthcare solutions. The company was built with the final consumer in its 
core - all the infrastructure and marketing-mix aimed to reach the final consumer being 
a classic B2C2 business model. However, as pointed from the investors the efficiency of 
the chosen business model was not crystal clear. In a sea of uncertainties one point was 
unquestionable: in order to grow from a startup to a key player in the operating market a 
clear path had to be set, an important decision had to be made.   
 
The company 
PharmAssistant is a Portuguese startup created in 2014 that focuses in developing a 
patient engagement solution in the digital health market to manage chronic diseases. 
The goal is to integrate several healthcare stakeholders in order to create synergies that 
will result in ingenious and quality healthcare solutions. 
                                                          
1 Acceleration program created by the Bayer Group that founds digital health startups and innovative health care 
projects. 
2 Classification of commerce transactions made from a business to a consumer. 
The following case study intends to provide relevant data for an informed discussion about the 
covered topics. However, to protect the confidentiality of the company, some data are disguised. 
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The company is developing a patient engagement solution, aiming to empower 
consumers with the control of their own health through a smart pill dispenser that had 
several improvements, as the company felt the dispenser did not reach its full potential 
(Exhibit 1) and a mobile app. It also intends to create a strong healthcare community 
network around the patient.  
The smart pill dispenser undermines the adherence to complex medication regimes 
through reminding the patient to take his medicines and controlling if the medication is 
taken. The new version is suitable for patients that take a high amount of medication, 
but as it is compact and portable fits even those who still have an active lifestyle. 
The mobile app adds all relevant health data (medication reminders, medical 
appointments, vital signs measurements and medical exams results) and can be 
connected to the smart pill dispenser for mobile notifications regarding medication 
usage. If the user is a patient in a partner hospital or clinic it can use the app to book 
appointments or to access electronically to his medical records. Through the usage of 
the pill dispenser to control the medication usage the app can also automatically control 
if the medication needs to be refill and order more medication in partner pharmacies.  
The app uses a special algorithm developed by the firm to calculate the level of 
alignment of the patient with his prescribed treatment. This app allows for a more 
customized health plan according to the patient’s need and circumstances.  
The regulatory system inside the digital health market is complex and evolving. 
Authorities’ approach to deal with the disclosure of health information varies widely 
from country to country. PharmAssistant is focusing in the US market that is legislated 
by the HIPAA Privacy rule. The Privacy rule permits covered entities that complaint 
with several administrative, physical and technical safeguards to disclose patient’s 
health information. This aims to assure the confidentiality, integrity and availability of 
the data. The company is HIPAA compliant and gives the consumer full control 
regarding who access his data. The company has a development center in Austin, Texas 
but the headquarters are in Lisbon, Portugal.  
To reach its consumers PharmAssistant tries to keep is message simple and clear. The 
team is aware it operates in a new market that may create some confusion in the 
consumers’ mind so the base of the entire communication is to “keep it simple”, as seen 





Figure 1 – Logo of PharmAssistant 
 
To reach consumers it relies on social media and a website were the benefits that the 
products bring to its users are communicate and explain. The website has a blog area to 
educate individuals and reinforce its position has a heath care specialist. To complement 
and channel patients to its website the company uses Facebook, Twitter and also 
participates in health care events and congresses not only to get noticed and educate the 
audience but also to attract potential investors.   
 
The CEO of PharmAssistant 
Diogo Ortega first glint of PharmAssistant occurred when his grandmother swap a pill 
by accident and he started thinking in a solution to help Mrs. Isilda to take the right pill 
at the right time.  
Diogo Ortega, CEO of PharmAssistant, has a passion for technologies. He started 
coding at the age of 15 and sold his first website when he was 17 years old. He studied 
Audiovisual and Multimedia Technologies and worked as a developer freelancer for 
mobile and web development while working at Vodafone. This gave him the knowledge 
to operate with several programming languages and systems (iOS, NodeJS, Python, 
SQL).  
He also worked at TAP Portugal as a flight attendant for six years and obtained a 
bachelor degree in Economics from the University of London. 
In December 2013 Diogo participated in the 24 hours Hackaton, event in 
which computer programmers and hardware developers present their ideas 
on software projects. It can have a contest element as well, in which a panel of judges 
select the awarded teams. He won the jury with his idea for a smart pill dispenser and a 
total prize of 14.000€. In 2014 he invested the money in a prototype and 
PharmAssistant was born. The company is formed by eight members committed in 
solving real-world problems and five strategic advisors. They earned several startup 
prizes as “Pirates on Shore” best pitch award, “Smart Equity” prize and in 2014 the 




Digital Health market 
With the increasing development of technology the convergence of the same with the 
health sector was one of the several paths to evolve. The development of expertise in the 
use of digital technology for medical and consumer health functions is empowering 
consumers with better solutions to access medical and personal health records, to 
manage a healthier lifestyle and improve their health resulting in the improvement of 
the society’s standards of living. This convergence is referred as digital health and 
allows relevant stakeholders to access real time applicable information in order to 
efficiently monitor patients, better manage chronic diseases and proactive preventive 
care.  The solutions booming inside this market can be integrated in the following areas: 
Telehealth that has strong regulatory barriers as the use of telecommunications and 
technologies for medical purposes bears strong safety challenges. Nevertheless this area, 
which allows patients to have medical advice without visiting a doctor, is expected to 
grow at a 50% annual rate until 20183. It has the potential to decrease the cost of health 
care services and bring care to more remote areas of the globe or even low-mobility 
patients. The biggest operator in telehealth is VSee, a world video telemedicine platform 
which allows patients from any part of the globe to have medical appointments via 
video-chat. Another area is behavior modification that is characterize through all the 
solutions that encourages patients to make healthier decisions. A Key player inside this 
area is the Health Grip group that developed the CareNotify app, a mobile messaging 
system that provides discharge instructions via secure messaging with real-time 
information about schedules, personalized education, and health-based screenings. It has 
a complete profile of each patient, organizes the schedules for his treatment and support 
patients throughout the continuum of care. The last area is remote patient monitoring 
that enables healthcare providers to keep track of patients' health. Remote monitoring 
tools include mobile apps and smart connected devices. Health care providers can know 
if the prescribed treatment is having the expected outcome without physically seeing the 
patient. Therefore the care delivery does not end when the patient leaves the hospital. 
The most innovative device in this area is Kinsa, a smart thermometer that scans your 
temperature, gives you a possible diagnostic and what diseases are spreading around in 
your community. 
                                                          
3 Source: Website: http://blog.linehealth.com/2015/11/5-digital-health-trends-that-will-change-your-life/ (Accessed 
on 1st of December 2015) 
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With the increasing per capita spending in healthcare, due to the ageing of population, 
increase longevity and more chronic conditions, the increasing introduction of e-health4 
initiatives by governments and proliferation of wearable and mobile devices, a growth 
in the digital health market is anticipated. Inside this market co-exist seven major 
regions: North America, Western Europe, Asia-Pacific Excluding Japan (APEJ), Japan, 
Eastern Europe, Latin America and Middle East & Africa. North America is the major 
region with a market share of 50%5 in 2014.  
Firms inside the digital health market follow a strategy of introducing new and costly 
effective solutions to buy out competition. Strategic alliances and joint ventures are also 
dominant strategies used to outperform competitors. The solutions being developed 
inside the mobile health market (mHealth) are expected to catalyze the growth of digital 
market around the globe.  Definitions of the mHealth market vary according to the 
integrated components. While is consensual that exist four dominant providers of 
mHealth technologies: health care providers, mobile operators, device vendors and 
content developers, the extension of the market is not. Assuming the market covers 
connected medical devices, healthcare applications and related mobile technology, the 
value of the market in 2013 was $2.4B and it is forecast to reach $21.5B by 2018 as 







                                                          
4 Healthcare practices integrated with electronic processes. 
5 Source: Website: http://www.futuremarketinsights.com/reports/digital-healthcare-market (Accessed on 4th of 








The health care stakeholders consist in the providers: a person who under federal 
regulations is authorized to practice in order to identify, prevent or treat illness or 
disability (e.g.: doctors and nurses); the payers: entities rather than the patient that 
support and finance the cost payed for the health care service (e.g.: insurance companies 
and government); the employers: institutions that are authorized by the law to provide 
the service produced by a health care providers (e.g.: clinics, hospitals, pharmacies and 
retirement homes) and the patients: a person how seeks the health care provider service 
in order to improve their wellness. An important force pushing health care stakeholders 
to change their traditional business model in the US is the 2010 Affordable Care Act 
(ACA), known as Obamacare. The act aims to improve patient satisfaction, increase 
outcome and decrease costs in the health care sector. The change in paradigm is force 
CAGR (Compounded Annual Growth Rate) 
Source: Mobile health technologies and global markets, BCC Research, 2014 
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due to the new freedom of choice given to consumers that are now in the center of the 
business strategy. The ACA allows individual to choose an insurance company 
according to their needs and preferences instead of being force to use the insurances 
plans available through their employers (ESI)6. Therefore, insurance companies need to 
focus their marketing efforts not only to reach companies, but also to attract individuals 
that can easily shift to a new insurance in order to get better prices, more coverage and a 
more satisfactory service which increases their marketing investments. Before the ACA, 
securing a deal with one client (a firm) would translate in several individuals, hence 
several contacts and several premiums. Nowadays, a deal with one client can lead to 
only one contract. Furthermore, with the increase of health costs many employers are 
dropping health benefits. These forces are increasing rivalry between insurance 
companies and differentiation stands as a crucial path for success. In order to be 
sustainable, insurance companies are looking for new and innovative methods that can 
allow them to reduce their costs and gain competitive advantage. In that sense, patient 
engagement, eCare and business development are gaining more relevance in the market 
as those solutions are innovative and aim to increase reduce the health care costs.   
In order to wider the national presence and gain more capital for investments, mergers 
are becoming a strategic path. Since the ACA passed the number of Accountable Care 
Organizations7 in the US increase from 64 to 7448. Estimations by McKinsey point that 
by 2025, ACOs will cover around 150 million people9. This new business model 
focuses in achieving more coordination between health care providers giving more 
quality solutions to patients. These organizations are also offering new patient oriented 
services10: electronic health records that can be access any time,  patient portals to 
access health data and communicate with doctors, electronic prescriptions directly 
transmitted to the patient’s pharmacy and solutions for remote monitoring and self-
diagnosis (devices, apps, programs).   
The sustainability of the digital health market lies in a complex thin balance between 
constrained budgets, the rising advance of medical treatments, increasing costs of 
                                                          
6 Employer Sponsored Insurance - Insurance coverage given by employers to their employees.  
7 Groups of health care provides that work together to deliver coordinated care. 
8 Source: Company website: http://blog.linehealth.com/2015/10/acos-whats-in-for-patients/ (Accessed on 5th of 
November 2015) 
9 Source: Company website: http://blog.linehealth.com/2015/10/acos-whats-in-for-patients/ (Accessed on 5th of 
November 2015) 




delivering care to an ageing population, increasing patient expectations demanding for 
better quality patient center health care and reduce availability aligned with increased 
costs of health care providers11. 
 
Competition  
Before entering in this market Diogo evaluated the competition and the team constantly 
access what the competitors are doing as they operate in a market where innovations are 
one of the few constants. The competitors of PharmAssistant can be divided in three 
categories. The companies that sell smart pill dispensers, firms that own digital health 
apps and pharmacies with a pill-pack service.  
Inside the pill dispenser segment operate AdhereTech, a US company founded in 2011, 
which sells a smart wireless pill bottle (Exhibit 2). The product collects and sends all 
adherence data in real-time. If medication doses are missed, patients can receive 
customizable alerts using automated phone calls and text messages. Compliance Meds 
Technologies is an emerging health technology company in the US that specializes in 
the implementation of innovative technologies to solve common medication use 
challenges. The Company’s lead product is Clever Cap (Exhibit 3), a smart pill lid that 
substitutes the cover of a standard pill bottle and reports to an encrypted platform that 
allows physicians and insurance companies access to patient data. CleverCap is 
equipped with audio and visual alerts to remind patients. MedMinder Systems is an US 
company that also has an automatic pill dispenser (Exhibit 4) that reminds users when it 
is time to take their medication through flashes, beeps, text messages and phone calls. 
All of these devices aim to undermine non-medication adherence and despite being 
patent protected, therefore changing in design and method to reach its purpose, they all 
reach the same goal: control and remind patients about their medication. The majority of 
companies that operate in this group of competitors sell their products directly to the 
final consumer what makes the CEO question if evaluating that almost all the other 
firms follow this business model did not unconsciously influenced its decision regarding 
PharmAssistant path. To build their cleaver pill boxes companies need raw material 
(plastic, plaster, aluminum and others) plus typical electronics components.  
                                                          
11 Source: Technology Enabled Care Services Resource for Commissioners, NHS Commissioning Assembly, January 
2015 & Deloitte report: Connected health, how digital technology is transforming health and social car. 
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Regarding mobile health apps the common categories are fitness apps and medical 
reference apps, as seen in graph 2.  
 
The most downloaded competitor is Argus. The app was created by the company 
Azumio which already developed other apps and is leader in fitness and health apps on 
mobile devices. Argus aims to facilitate users to follow a healthier lifestyle by allowing 
them to track their general health (weight, water consumption, sleep and others) through 
connecting to third-party gadgets. Another competitor is Healthmemo that allows users 
to upload and maintain their health records electronically. Carrying around all the health 
records a patient has, like prescriptions, x-rays, lab reports and so on, is tedious and 
unpractical. The apps aims to solve this problem and allows users to share their records 
with health care providers. In order to create those apps, as they deal with extensive 
amounts of data, a virtual space to storage all the data is necessary. Those spaces are 
denominated as clouds – a datacenter full of servers that is connected to the 
Internet. Clouds also followed the development of technologies offering more services 
than just data storage but only data storage is strictly necessary for digital health 
companies that operate in the mobile health market. Several companies are offering this 
service but the most relevant are Amazon, Microsoft, IBM and Google. This is a service 
that can be produce in-house by companies inside the market: the question managers 
need to make to themselves is if that is the most efficient allocation of resources. The 
mobile applications market is one of the fastest growing market in the globe. According 
to VisionMobile estimations, app store sales will generate around 43 billion dollars in 
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revenues in the end of 2015. Companies operating in this market compete more directly 
as for consumers comparing competing apps within category is easier than, say, 
comparing music offerings within a genre (Gunwoong Lee and T.S. Raghu, 2014). Also 
in this market, the crucial determinants for a higher probability of app survival are free 
offering, higher debut rank, investment in less popular categories, continuous feature 
updates, and higher user review scores on apps (Gunwoong Lee and T.S. Raghu, 2014). 
The final group of competitors are Pharmacies that offer a pill-pack, a service of 
medication delivery where the pills are packed in a specific order, coherent with the 
patient medication usage (hour and day).  
 
Consumers 
For the team the consumer is in the core of its business. Diogo always tried to 
implement a company culture where the consumers are no stranger to the company and 
the solutions they create are develop around the patient. Since 2012, is estimated that 
about half of all US adults (≥18) had at least one chronic health condition (Exhibit 5). 
With a growing population of chronic patients, engagement is essential to drive costs 
down and improve outcomes in health care. Chronic diseases were, in 2010, seven of 
the top 10 causes of deaths in the US12. Heart diseases and cancer together accounted 
for almost 48% of all deaths. 
Evidences suggest that patients that are not actively engaged in their health care incur 
costs up 21%13 higher than engaged ones. Furthermore, every year 125,00014 
individuals die in the US due to non-adherence to medication, leading this issue to be 
one of the major challenges of today’s health care sector. Estimations15 point that 50% 
of medication is not taken as prescribed which increases the annual costs of the US 
health care sector by $290B due to the reduction in the efficiency of treatments.  
Hospitals are spending around $25B16 a year as consequences of high readmission rates 
that could be prevented with more patient engagement and adherence to prescribed 
                                                          
12 Source: Centers for Disease Control and Prevention. Death and Mortality. NCHS FastStats  Website: 
http://www.cdc.gov/nchs/fastats/deaths.htm  (Accessed on 3rd of November, 2015). 
13 Source: Company report - Patient Engagement: The key for sustainable healthcare, September 2015 & Health 
Affairs Policy Brief, 2013. 
14 Source: Company report - Patient Engagement: The key for sustainable healthcare, September 2015 & ATREJA A, 
BELLAM N, LEVY S, Strategies to enhance patient adherence: Making it simple. Medacapt Gen Med, 2005. 
15 Source: Company report - Patient Engagement: The key for sustainable healthcare, September 2015 & Thinking 
outside the pillbox, New England Healthcare Institute (2009). 
16 Source: Company report - Patient Engagement: The key for sustainable healthcare, September 2015 & Price of 
Excess: Identifying Waste in Healthcare, PWC (2008) 
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treatments. Non-adherence to medication and lack of treatment engagement causes 
patients to fail in filling prescriptions, which costs the pharmaceutical industry in the 
US around $564B17 or 37% of potential revenue each year.   
Technology is a crucial area for patient engagement; innovations inside this sector 
empower patients with their own health and build a strong community around them. 
From smart devices to mobile platforms all are grounding area to build patient-centric 
solutions. These devices are part of US’s adults (≥18) daily life, only in the older 
population (65+) we cannot state that more at least 1 in each 2 adults has a smartphone 
(Exhibit 6). However, according to the Deloitte’s Telecommunications Media and 
Technology Predictions 2014 report the over 55 years of age group will experience the 
fastest year-on-year rises in smartphone penetration across developed markets 
decreasing the gap with the younger groups until becoming trivial by 2020 (see Exhibit 
7 for smartphone penetration as of May-June 2013).  The percentage of smartphones 
usage according to gender does not vary much (Exhibit 8) and the most used mobile 




The drivers leading Americans to their smartphones are also changing. In the past 
gaming had extensive year to year usage growth rates, however in 2013-2014 it only 
register a growth of 30% while health and fitness had a growth of 89% (Exhibit 9). 
Adding, 69% of U.S. adults keep track of at least one health indicator (such as weight, 
                                                          
17 Source: Company report - Patient Engagement: The key for sustainable healthcare, September 2015 & Estimated 
Annual Pharmaceutical Revenue Loss due to Non-adherence, Capgemini Consulting & Health Prize 
Graph 3 -  
Source: Nielsen, Data based on Nielsen’s monthly survey of 30,000+ mobile subscribers aged 13+ in the U.S. 
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diet, exercise routine, or symptoms)18; 2 out of 3 people would consider switching to a 
physician who offers access to medical records through a secure internet connection19; 
80% of Americans with access to electronic health records use it20 and 77% of patients 
want to book appointments online and get appointment reminders in their email or 
cellphone21. Physicians are aware of this increasing demand for technologic health 
solutions as showed by the increase in the use of electronic health records system from 
18% to 57%22. Pharmaceutical companies are also attempting to adapt to the consumers 
changes, using apps and wearable devices to collect patient data to support research and 
provide a more technologic service to them. The leading pharmaceutical companies had 
an increase of 63% (Exhibit 10) of unique health apps in apps stores from 2013 to 2014 
and the number of downloads of the same increased 197% (Exhibit 11) in the same 
period.       
In order to gain more knowledge about the acceptance and buying factors of chronic 
patients for the solutions being developed inside the digital health market Deloitte 
survey 1,130 people with a long term condition in 2014. The report suggests that the 
most relevant features to drive purchases for health apps are: disclosure of accurate 
information, easiness of use and security (Exhibit 12). Regarding the patients 
perceptions of necessary features for the health apps the most relevant are: 
understandable information on medical conditions, systems to help communicate with 
health providers and access to health records and tracking services (Exhibit 13).  
 
What’s the future? 
In August 2014 the PharmAssistant’s team moved to Berlin as part of the Grants4Apps 
acceleration program to test their product with the partnership of the German company. 
PharmAssistant grasped the opportunity in Leverkusen, Germany, to interview 
consumers and critical partners inside the health care sector. This research provided the 
team with new information about the market that was not accessible with the previous 
resources due to the know-how that Bayer acquire from being a global enterprise with 
core competencies in the health care sector. The firm also conducted a product-use test 
                                                          
18 Source: Pew Research Center’s Internet & American Life Project, 2013 
19 Source: Survey of Health Care Consumers in the United States: Key Findings, Strategic Implications, Deloitte 
Center for Health Solutions, 2011 
20 Source: Making IT Meaningful – How Consumers Value and Trust Health IT, National Partnership for Women and 
Families, 2012 
21 Source: Great Expectations: Why Pharma Companies Can’t Ignore Patient Services, Accenture, 2013 
22 Source: NCHS Data Brief n.79, November 2011 
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were a small group of potential consumers used the product for a limited time. The main 
conclusions from the research in Germany were: the control if the medication was taken 
was flawless, some patients in order to stop the reminders (the flashing lights and alarm 
of the pill dispenser or the smartphone notifications if the two devices were connected) 
would open the compartment with the pill and close without taking out the medication 
as, at that moment, they were occupied with other matters. The process of taking the 
medication from its original box and setting it in the pill dispenser compartments 
damaged the medication through the exposition with the nature elements and regarding 
health care providers patients are loyal to them due to convenience, confidence and 
security.  
 
Task at hand  
The problem of medication non-adherence is a big burden for US's health care systems, 
at this point PharmAssistant envisions two directions to address this problem: continue 
following a B2C business model, targeting the elderly population and young adults with 
chronic diseases, focusing mainly in consumers that have expensive medication or/and 
the treatment needs to be strictly followed. The other direction is to reach the same end 
user using relevant stakeholders inside the health care sector as a distribution channel. 
So, the company would sell its products to these stakeholders involving more partners 
in addressing the non-adherence to medication problem, developing a B2B business 
model. 
To capitalize the knowledge and enthusiasm the team built in Berlin, Diogo Ortega 
already scheduled a reunion for the next week. It’s time to go back to the dashboard and 
figure out a clear definition of the expected consumer base. Only afterwards 
PharmAssistant can better meet the needs of the potential consumer, tailor the products 
to them, target the marketing efforts to reach them and craft the messages appropriately. 
Therefore, is imperative to clarify and identify the desirable target. In order to reach that 
goal the following chain of question has to be taken into consideration: 
 Is the current target of PharmAssistant the most desirable one? 
 If the current target is not desirable, what should be the new target for 
PharmAssistant? 
 Considering the first two questions, what measures can PharmAssistant adopt to 




Exhibit 1 – Evolution of the PharmAssistant smart pill dispenser     
















Exhibit 4 – MedMinder automatic pill dispenser 
   
  
Most recent version of 




Exhibit 5 – Table of Estimated percentage of US Adults aged ≥18 with chronic 
conditions, USA Health Interview Survey, 2012 
 
Abbreviation: CI, confidence interval. 
a Chronic conditions include hypertension, coronary heart disease, stroke, diabetes, cancer, arthritis, hepatitis, w
eak or failing kidneys, current asthm
a, and CO
PD. 
b Population in 1,000s. 
c Total 2012 US adult population: 234 m
illion persons. 
d Adults identified as m
ultiple races w
ere included in the “other race” category. 
e Health insurance coverage w
as based on a hierarchy of m
utually exclusive categories. Public health insurance coverage includes M




ther health insurance coverage includes state-sponsored health plans, other governm
ent program
s, and m
ilitary health plans.  
  Estim
ates w
ere calculated for subgroups defined by age, sex, race/ethnicity, and health insurance coverage to show
 prevalence of single conditions and m
ultiple chronic conditions 
am
ong these subgroups. Tw
o-tailed significance tests w
ere used to test for differences in prevalence betw
een population subgroups; all differences reported are significant (P < .05). 
 Source: W
ard BW
, Schiller JS, Goodm
an RA. M
ultiple chronic conditions am
ong US adults: a 2012 update W





















[18-24] [25-34] [35-44] [45-54] [55-64] 65+
Source:  Deloitte Global Mobile Consumer Survey, Developed countries, May-July 2013 
*Weighted base: (respondents from all age groups) Belgium (2,000), Finland (1,000), France(2,000), Germany (2,000), 
Japan (2,000), Netherlands (2,009), Singapore (2,000), South Korea (2,011), Spain (2,000), UK (4,020), US (2,000)
 Exhibit 6 – US mobile market share by age 
 














Source: Nielsen, Data based on Nielsen’s monthly survey of 30,000+ mobile subscribers aged 13+ in the U.S. 
Source: Nielsen, Data based on Nielsen’s monthly survey of 30,000+ mobile subscribers aged 13+ in the U.S. 
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Exhibit 9 – Growth rate of mobile usage 
 
 
Exhibit 10 – Number of unique* health apps published by leading pharmaceutical 
companies 
 













Source: Pharma App Benchmarking, research2guidance, 2014 













Source: Pharma App Benchmarking, research2guidance, 2014 
Source: Flurry Analytics. Flurry Analytics tracked 2.079 trillion app sessions on iOS and Android 
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Exhibit 12 – Purchase drivers of health apps 
 







To address the PharmAssistant dilemma three research question were made in the 
beginning of the dissertation. In order to have information to address those questions 
market research regarding the market, the consumers, the competitors and the company 
was made.  
PharmAssistant was created 2 years ago and the owner feels to move from a startup to a 
key player in the operating market it needs a clear vision about the path to follow.  
 Analyzing the data from the research the digital health market is an attractive market 
and PharmAssistant should use its resources and capabilities to outperform its 
competitors in the market and sustain higher profits. To do so, the firm first needs to 
know who to target its products and after, how. The dissertation main question is 
regarding the how, as the team doubts the current target is the most efficient.  
Targeting is at the base of a company’s marketing as only after selecting the most 
profitable segments a company can adjust its marketing mix to accurately address the 
potential consumer needs. Currently, as all of its direct competitors, the company is 
targeting consumers with one or more chronic conditions, however another path to 
reach the same users is to sell its products to businesses that afterwards will sell the 
product to the final user. The possible businesses are the health care stakeholders that 
could benefit from selling the smart pill dispenser and the mobile app (clinics, hospitals, 
pharmacies, retirement houses and insurance providers). After analyzing the relation of 
those stakeholders and the easiness they could reach the end-user the businesses that 
comprise the new potential target are clinics, hospitals, pharmacies and private 
insurance companies. Through integrating the company resources, their competitors’ 
strategies and the forces affecting the market is possible to access if PharmAssistant has 
resources that allow the company to follow the current path and reach consumers 
throughout the US in order to outperform its competitors or if the most desirable path is 





This dissertation is limited as focus mainly in who is the desirable consumer. It 
proposes generally how the firm should reach its desirable target without concrete proof 
that those measure are the most efficient. Through not considering more detailed 
information about clinics, hospitals, pharmacies and private insurance companies, it 
does not allow for the developing of a more informed opinion regarding the desirable 
positioning the company should adopt after the decision of the target change. 
Nevertheless, there is no evidence to suspect that the decision of the target change 
would be different taking into account this aspect.  
Also, it could be interesting to include more information about the purchasing habits of 




7. Teaching Note 
 
7.1. Synopsis 
The presented case aims to elucidate students on marketing topics of targeting, 
competitive advantage and its influence in the brand’s sustainability through the 
analysis of a real business dilemma faced by a Portuguese startup.   
The following section pretends to guide the teaching of the case written in the extend of 
a Master of Science in Management thesis, with the collaboration of the Portuguese 
startup PharmAssistant.  
PharmAssistant is a Portuguese startup that by creating a smart pill dispenser and a 
mobile app that connects to the previous device pretends to develop a patient 
engagement solution in the digital health market to manage chronic diseases. The case 
study explains the path the firm made so far, highlighting the crucial forces that 
influence the market, the consumers’ behavior and the degree of competition. 
The entire case evolves until reaching the crucial dilemma that Diogo Ortega, the CEO 
of the company, is facing now due to new information accessible after four intense 
months of marketing research in Berlin with the global health care enterprise Bayer. 
Diogo and his team must decide between continue following a B2C business model, 
targeting the elderly population and young adults with chronic diseases or targeting 
relevant stakeholders inside the health care sector developing a B2B Business model. 
Then those stakeholders would sell the products to the end-user. The dissertation 
provides information to help students put themselves in the role of the CEO in an 
attempt to form a sustained opinion for the resolution of the dilemma. 
 
7.2. Target audience and Teaching objectives 
This case study is suitable to enhance the students’ learning process in undergraduate 
marketing lectures or master level marketing lectures for students without previous 
background in management. It aims to connect different marketing concepts, as 
targeting, segmentation, competitive advantage, in order to develop a clear 
understanding of marketing management practices. Thus, testing the students’ 
knowledge of general introductory principles and application of marketing.  
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The dissertation provides not only a theoretical learning, but also a practical approach 
where students will make crucial decisions for the sustainability of the Portuguese 
startup PharmAssistant in the digital health market. The CEO of the company is facing a 
crucial dilemma, should the company change its current target or not. Through adopting 
the role of the startup CEO students will have the necessity to select the most relevant 
data to reach a structured and sustain decision for the resolution of the firm’s dilemma. 
Although the following section provides a clear resolution for the case, to foster in-class 
discussion different perspectives and solutions should be accepted as long as they are 
coherent and strongly reasoned.   
  
To complement the case study and highlight some key marketing concepts in the 
students’ minds the following readings are suggested: 
 Kotler, P., Wong, V., Saunders, J., Armstrong, G. (2005). Chapter 10 
Segmentation and positioning. In Principles of marketing, 4th European ed., 
Pearson Prentice Hall. 
 Ormanidhi, O., Stringa, O. (2008). Porter's Model of Generic Competitive 
Strategies. Business Economics, 43(3), pp.55-64. 
 Ende, J., Jaspers, F., Rijsdijk, S. (2013). Should System Firms Develop 
Complementary Products? A Dynamic Model and an Empirical Test. Journal of 
Product Innovation Management, 30(6), pp.1178-1198. 
 
7.3. Teaching Plan 
To enhance the class discussion and allow students to have more lens to analyze the 
case study is recommended that the students read, at home, the readings mentioned in 
the teaching audience and teaching objectives section, before the lecture. The proposed 
resolution guides the students during the lecture through several questions directing 
them to the resolution of the “task at hand” for the CEO of PharmAssistant. 
1. Characterize the digital health market in terms of solutions and attractiveness. 
The solutions inside this market can be separated in three areas: 
 Telehealth, which allows patients to have medical advice without visiting a 
doctor;  
 Behavior modification that are all the solutions that encourages patients to make 
healthier decisions;  
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 Remote patient monitoring that enables healthcare providers to keep track of 
patients' health.  
The Porter’s 5 Forces Model can be used to determine qualitatively the market 
attractiveness. The model analyzes five competitive forces of the market to infer the 
level of competition within firms and consequently the industry attractiveness. These 
forces are part of the micro environment as they consider the firm ability to serve its 
customers and be profitable.  
Threat of New Entries 
The level of entrance barriers determines the level of threat of new entries. Profitable 
markets will attract new firms. If firms can freely enter those markets, the profitability 
of all firms in the industry will decrease. Theoretically firms will enter until the industry 
profit reaches zero (perfect competition). The regulatory system inside the digital health 
market is complex and evolving. In the US market the digital health market is legislated 
by the HIPAA Privacy rule. The Privacy rule permits covered entities that complaint 
with several administrative, physical and technical safeguards to disclose patient’s 
health information. This acts as an entry barrier since firms without HIPAA approval 
cannot operate as effectively in the market.  
Firms inside the market follow a strategy of introducing new and costly effective 
solutions to buy out competition. This also acts as a barrier, as high initial investments 
are need, what decreases the number of new market entrances.  
Several technologic solutions that are booming inside this market, as the pill dispensers, 
can be patent protected preventing competitors to imitate their method of serving 
consumers and forming an entry barrier.  
Taking the analysis above into consideration, the threat of new entrances in the digital 
health market can be characterize as low.   
Bargaining Power of Buyers 
The bargaining power of buyers is determined through the costumers’ ability to exert 
pressure in the firms operating in the market. Inside the digital health market we can 
distinguish two buyers: final consumers and resellers. Regarding the final consumer, as 
the digital health market is still gaining expression the number of firms operating inside 
the same remains limit and consumers have a small assortment of firms to choose from. 
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This increases the consumers switching costs and undermines their power to exert 
pressure in terms of product margins.  
Before characterize the resellers’ power is necessary to identity them. When stating 
resellers we are talking about health care providers, more specifically the government, 
pharmacies, insurance companies, clinics and hospitals. Resellers differ from the final 
consumers as they buy several units of the product and they are crucial touch points 
with the end consumer. Therefore they have power to exert pressure on firms. As a 
whole, the bargaining power of clients in this industry is medium. 
Threat of Substitutes 
The threat of substitutes is characterize through the existence of products or services 
that satisfy the same needs as the products inside the operating market allowing 
customers to switch to alternatives from other markets. 
The goal of products and services inside this market is to increase patients’ adherence to 
the prescribed treatments and improve the quality of health care solutions. Due to the 
technologic innovation of this market is not possible to identify direct substitutes. 
However, a home-nurse/doctor service and retirements homes, in the case of elderlies 
that are a specific segment inside this market, can be stated as indirect substitutes. So, 
the pressure of substitutes in the digital health market is low 
Bargaining Power of Suppliers 
The Bargaining power of suppliers is determined through the suppliers’ ability to exert 
pressure in the firms operating in the market. A supplier has power if firms cannot find 
an alternative one. Of course, in a market that is driven through innovation, new 
solutions that break the paradigm from a day to another can emerge. However, the 
technologic solutions build in the digital health market rely in big data coding and 
storage (for example the software supporting an app or the data from a patient that is 
being monitored). So, companies need to contact a supplier that sells them a virtual 
space to storage their data, what we call nowadays a cloud – a datacenter full of servers 
that is connected to the Internet. Clouds also followed the development of technologies 
offering more services than just data storage but the one that is strictly necessary for 
digital health companies is that one. The major companies offering this service are 
Amazon, Microsoft, IBM and Google. Nevertheless, other companies with small 
expression operate in the market forming a diverse supplier assortment and decreasing 
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the power of suppliers. Other solutions in this market are physical products (for 
example pill dispensers and tracking wearables) that need raw material (plastic, plaster, 
aluminum and others) plus electronics components to be build. Several companies 
specialized in producing those materials increasing the number of options therefore 
decreasing the supplier power.  
Digital health mobile companies could develop those services in house, however is 
more efficient for them to contact suppliers that are specialized in the services above 
described.  
Concluding, the evidences above support that the bargaining power of suppliers is low.           
Intensity of rivalry 
The intensity of rivalry is an indicator of the competition within firms inside the market. 
The solutions inside this market evolve around technology innovations that can be 
patent protected and also drive competitive advantages. While the competitive 
advantages, as are created from differentiation, reduce the rivalry, the high level of 
investments necessary to achieve those technologic innovations increase the barriers to 
exit. Also, companies inside this market keep finding similar ways to achieve the same 
goal upsetting the effect of patents. These arguments support that the rivalry inside the 
digital health market is medium. 
The analyses of the 5 forces supports that the attractiveness of the digital health market 
is high. This industry attractiveness does not imply that every firm that enters this 
market will be profitable. 
2. Does PharmAssistant have an end user “slice” large enough to justify the 
presence in the market? (Please separate you analyze according to the products the 
firm offers.) 
Table extrapolated with calculations from exhibit 1   
 
1 Chronic conditions 2 Chronic conditions ≥3 Chronic conditions Percentage of population
Male 27.248 14.685 12.060 22,98%
Female 29.906 17.666 15.356 26,79%
57.154 32.351 27.416 49,77%
Age group [18-44] 21.590 5.616 2.208 12,52%
[45-64] 25.100 15.168 11.329 21,96%
≥65 10.464 11.566 13.879 15,29%





Data extrapolated from the case study allows us to grasp that the segment of patients 
with chronic conditions covered nearly 50% of the population.  The distinction in male 
and female could be relevant in terms of design choices.  
The distinction between ages allows to understand inside the chronic individuals the 
segments that are eligible to use the mobile app and not only the pill dispenser. Data 
from the case study (exhibit 2) indicates that in the segment of individuals with more 
than 65 years old only 46.3% uses a smartphone (much smaller than the other 
segments). Therefore for the mobile app the company should focus only on the other 
age segments that corresponded around 35% of the population. However, the team 
should have in mind that predictions from the Deloitte’s Telecommunications Media 
and Technology Predictions 2014 report that the over 55 years of age group will 
experience the fastest year-on-year rises in smartphone penetration across developed 
markets decreasing the gap with the younger groups until becoming trivial by 2020. 
Regarding the pill dispenser as it is suitable for patients that take a high amount of 
medication, but as it is compact and portable fits even those who still have an active 
lifestyle all age segments are potential users. The key determinant to gain consumers in 
the younger segments is to show the value that the two products can bring to their life 
on top of reminding them to take their medication.   
Adding, according to the case the predicted growth of revenues in the mobile health 
market will reach $21.5B by 2018. 
In conclusion, PharmAssistant has a segment large and profitable enough to justify the 
investments in the digital health market.  
 
3. Characterize the digital health market competition according to the solution 
they offer. 
 






Azumio Remote patient monitoring & Behavior modification
Healthmemo Remote patient monitoring






4. What is the core product for PharmAssistant and what product serves as a 
complement? Should the company develop the two products? 
PharmAssistant has two products, a smart pill dispenser that undermines the adherence 
to complex medication regimes through reminding the patient to take his medicines and 
a mobile app that allows for a more customized health plan according to the patient’s 
needs. The app has six main features: medication reminders, medication usage control, 
automatic medication pharmacy refill, vital signs measurements, online medical 
appointments booking and electronic medical exams results. Of the six main features 
only the latter three can be used without the connection to the pill dispenser. Therefore a 
user can only use 50% of the app functionalities if the app is not connected to the smart 
pill dispenser. On the other hand, if the user only purchase the smart pill dispenser it can 
use 100% of its functionalities. Hence the company main product is the pill dispenser 
and the app acts as a complement. PharmAssistant is developing two innovative 
products in a recently new market and sustain in the arguments of Ende, Jaspers, and 
Rijsdijk (2013), to whom “firms should be strongly involved in complementary product 
development when they introduce a new core product, and even more so if the 
complementary products are new” the company should develop the two products. 
5. If PharmAssistant decide to change business model, what other targets could the 
firm pursue? Is this the most desirable decision? 
For PharmAssistant changing business model means developing a B2B business model 
instead of B2C. Starting the analysis by looking at all the stakeholders inside the digital 
health market and selecting the ones that correspond to a business is possible to identify 
two potential target segments of stakeholders: the payers and employers thus excluding 
the group of providers and patients. With the help of the case is possible to identify if 
the specific group of stakeholders has a problem that the PharmAssistant products 
allows them to solve. For this case the need was identify as a cost problem: will the 
patients’ products use allow the stakeholders to incur in major cost savings? If the 
answer is yes the stakeholders can be primarily identify as a target since this is a 
sufficient purchase driver. Adding, the stakeholders that are going to be analyze already 
have selling points in their facilities and resources to make sells so the other relevant 
feature is if the stakeholder is a touching point with the end user thus avoiding any cost 
to attract consumers to the point of sale.    
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Employers: institutions that are authorized by the law to provide the service produced 
by a health care providers 
 
Payers: entities rather than the patient that support and finance the cost payed for the 
health care service  
 
While in the case of the employers is straight forward that they are a touching point 
with the end user as they are the only place where patients can be treated, to know if the 
insurance provider is a touching point is necessary to know from the patients that have 
chronic diseases what percentage has a private or public health insurance coverage. The 





Patients that are not 





Type Why/How User touchpoint?
They have several nurses 
to take care of their 
patients that act as a 
substitute for the products
Retirement homes No
Yes, primarily in 
the case of the 
65+ segment
Yes
Are spending around 
$25B a year as 
consequences of high 
readmission rates
Yes
Failure in filling 
prescriptions costs 
around $564B a year
YesPharmacies Yes
Hospitals
50% of medication is not taken 
as prescribed increasing the 
annual costs of the US health 



















Percentage of target 
population 
Private  37 216 19 298 13 844 60,13% 
Public 9 778 8 635 10 850 25,01% 
 
From the table is clear that only the private insurance companies can be considered as a 
touching point.  
Adding all the information above is possible to state that the potential B2B targets for 
PharmAssistant are clinics, hospitals, pharmacies and private insurance companies.  
Assessing if this targets are the most desirable ones for PharmAssistant is a more 
debatable topic. Most of the competitors that operate in this market sell their products 
directly to the final consumers, hence one may argue that PharmAssistant should imitate 
their competition and follow the same path. So, in order to outperform its competitors 
PharmAssistant must gain competitive advantage – the use of its resources in a way that 
allows the company to perform at a higher level than its competitors. According to 
Porter there are 3 generic ways to achieve it:  
 Cost leadership, through offering the products at the lowest cost in the digital 
health market; 
 Differentiation, address the consumers need in a unique way in the digital health 
market; 
 Focus on a narrow target with specialized needs. 
The main question Diogo needs to make to his team is if the available resources of the 
company allow them to reach any of the above paths. Being a startup in the market, 
PharmAssistant needs place itself as a top of the mind brand in this market what 
involves marketing costs. The firm is operating in a recently new market so there is a 
cost associated with educating consumers.  Adding, the pilot-test in Berlin showed that 
the product still needs improvements what is going to also increase costs. All these 
aspects are contradicting with a cost leadership path. The innovations inside this market 
are expensive as they required high investments and companies operating in the market 
follow a strategy of introducing new and costly effective solutions to buy out 
competition through strategic alliances and joint ventures. Also, companies inside this 
market keep finding similar ways to achieve the same goal upsetting the effect of 
products’ patents. These points undermine the company ability to differentiate from its 
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competitors. The only path that seems pursuable is to focus on niche target with 
specialized needs.  
Through selling their product to the stakeholders stated above PharmAssistant will 
involve more stakeholders in addressing the non-adherence to medication problem. In 
terms of infrastructures and marketing expenditures selling the products to clinics, 
hospitals, pharmacies and private insurance companies is more effective as these clients 
will make purchases in higher quantities and do not require education about the 
products. Furthermore, as concluded above these stakeholders already have a need that 
the product solves and the infrastructure to reach the end-users of the product. Another 
argument sustaining the change in target is that the stakeholders that are losing more 
money due to the non-adherence problem in the US are the employers therefore being 
more desperate for an effective solution for this problem.  
Concluding, while debatable the desirable solution for PharmAssistant is to change its 
target.   
  
6. Taking into account the most desirable target for PharmAssistant what 
measures the company should adopt to reach its (new) target?  
Regardless the desirable target, some aspects regarding the two products should be 
improve. The test marketing conducted in Berlin highlighted two performance problems 
of the smart pill dispenser. The failure in controlling the medication usage what 
undermines two features of the app, directly, the medication control and, indirectly, the 
automatic medication pharmacy refill. The other failure was the decrease of the 
medication efficiency due to the process of setting the medication in the smart pill 
compartments. Those failures need to be addressed and solved in order to meet the 
needs of the end user in a more accurate method.  
Regarding the mobile app the case study provides evidence on the crucial determinants 
for an app success in the market. From those the ones that are relevant for 
PharmAssistant are higher debut rank, continuous feature updates, and higher user 
review scores on apps. So PharmAssistant must capitalize in the knowledge of the 
global enterprise Bayer to develop an app with a high quality without bugs23. 
Furthermore, the company must have recall that for a regular use of the product the app 
must be data secure, user-friendly and provide trustworthy information (conclusions 
                                                          
23 Flaw in the app that provides an unexpected result or leads the app to behave in unintended forms.    
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from exhibit 8). Adding, users are mainly expecting from the app the ability to 
understand symptoms and medical conditions, the possibility to communicate with 
doctors, the access to medical records and the power to track their medical conditional 
(conclusions from exhibit 9).  The current app of PharmAssistant does not allow to 
understand symptoms or to communicate with health care providers. Therefore, those 
are aspects that the firm may consider to develop in feature versions of the mobile app 
(for example it could connect with the smart thermometer kinsa that already allows 
users to have a possible diagnostic). Of the six available features in the mobile app three 
are depending of a health care provider: automatic medication pharmacy refill, online 
medical appointments booking and electronic medical exams results. Furthermore, the 
interviews made to consumers and critical partners showed that patients are loyal to 
health care providers and develop a relation based in aspects as convenience, confidence 
and security. Those last two aspects, as stated before, are crucial for the regular use of 
the app. PharmAssistant must build on the existing patients’ relations and partner with 
several hospitals, clinics and pharmacies as they add value to the mobile app while 
retrieving value from the saving in costs due to more engaged patients, thus building a 
strong network around the final user. 
If the student sustains that the firm should keep the actual target then he must state that 
the team should develop a differentiated marketing campaign due to the difference in 
characteristics and technology usage habits of target consumers. For the segment of 65+ 
where, for now, only the smart pill dispenser should be communicate special emphasis 
should be made in communicating the easiness of following and controlling complex 
medication usage. 
The other segment is the younger groups where both the smart pill dispenser and the 
mobile app should be commercialize. For this target special emphasis should be made in 
communicating the convenience of carrying only one dispenser instead of several pill-
boxes or blusters of pills and the benefits of controlling our health with the point of our 
fingers.  
If the student sustains that the firm should change the actual target than he must argue 
that the company should change its communication, the drivers that leaded the 
company’s target to make a purchase completely change so the communication needs to 
change accordingly. PharmAssistant now needs to give special emphasis in 
communication the savings in costs the usage of the product will give to each business. 
The student can go even further and state the PharmAssistant should do a rebranding. 
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The company is still a startup without any clear position in consumers’ minds so the 
rebranding will nor create confusion in the consumers. From the case is clear that the 
company was built with the individual consumer at its core and the cartoonish logo and 
company name were drown to appeal to an individual. Through selling to a business 
other aspects than having a non-complex image and message gain relevance (for 
example showing a serious and professional image). PharmAssistant should research 
about its new target and rebrand creating a new brand that appeals to it. To build all the 
new brand elements the firm must have in mind that the building criteria for the 
elements are to be memorable, meaningful and likeable. 
After the successful implementation of the case study in the lectures students must be 
able to: 
 Understand the forces that influence the digital health market and analyze the 
market’s attractiveness; 
 Perceive the importance of correctly segmenting and targeting the market and 
the implications of that decision for the brand; 
 Grasp the implications of a target change in a company business and the extent it 
affects the brand’s communication; 




8. What happen? The new PharmAssistant 
In line with the main product failures exhibited in the marketing test conducted in 
Berlin, the company developed a new smart pill dispenser that uses the pill pack 
prepared by pharmacies to avoid any pill contact with the natural environment. To avoid 
that consumers open the pill compartment just to stop the reminders without taking the 
pill, in the new pill dispenser users can only stop the reminders by clicking in the pill 
compartment that will release the pill. Thus, allowing for a better consumption control. 
 
After several meetings Diogo and its team decided that the most efficient path was following a 
B2B business model. As the team members felt the company lacked a professional and serious 
image that would appeal to the new target a rebranding that will result in a new firm - Line 
Health - is being made. 





Atreja, A., Bellam, N. and Levy S. (2005). Strategies to enhance patient adherence: 
making it simple. The Medscape Journal of Medicine, 7(1); 
Audia, P., Locke, E. and Smith, K. (2000). The paradox of success: an archival and 
laboratory study of strategic persistence. Academy of Management Journal, 43(5), 
pp837-853; 
Barney, J. (1991). Firm resources and sustained competitive advantage. Journal of 
Management, 17, pp99–120; 
Blattberg, R., Buesing, T., Peacock, p. and Sen, S. (1978). Identifying the Deal Prone 
Segment. Journal of Marketing Research, 15(3), pp369-377; 
Bowman, C. and V. Ambrosini (2000). Value creation versus value capture: towards a 
coherent definition of value in strategy. British Journal of Management, 11, pp1–
15; 
Caves, R. and Porter, M. (1977). From entry barriers to mobility barriers: conjectural 
decisions and contrived deterrence to new competition. Quarterly Journal of 
Economics, 91, pp241–262; 
Chamberlin, E. (1965). The Theory of Monopolistic Competition. Cambridge, MA: 
Harvard University Press; 
D'Aveni, R., Dagnino, G. and Smith, K. (2010). The age of temporary competitive 
advantage. Strategic Management Journal, 31(13), pp1371-1385; 
Dibb, S. and Simkin, L. (2009). Implementation rules to bridge the theory/practice 
divide in market segmentation. Journal of Marketing Management, 25(3/4), pp375-
396; 
Dickson, P. and Ginter, J. (1987). Market Segmentation, Product Differentiation, and 
Marketing Strategy. Journal of Marketing. 51(2), pp1-10; 
Dyerson, R., Harindranath, G., Huang, K. and Wu, L. (2015). From Temporary 
Competitive Advantage to Sustainable Competitive Advantage. British Journal of 
Management, 26(4), pp617-636;  
Ende, J., Jaspers, F. and Rijsdijk, S. (2013). Should System Firms Develop 
Complementary Products? A Dynamic Model and an Empirical Test. Journal of 
Product Innovation Management, 30(6), pp.1178-1198; 
45 
 
Galbraith, J. (1967). The New Industrial State. Boston: Houghton-Mifflin Company; 
Greengrove, K. (2002). Needs-based segmentation: principles and practice. 
International Journal of Market Research, 44(4), pp405-421; 
Kotler, P., Wong, V., Saunders, J., Armstrong, G. (2005). Chapter 10 Segmentation and 
positioning. In Principles of marketing, 4th European ed., Pearson Prentice Hall; 
Lancaster, K. (1979). Variety, Equity, and Efficiency. New York: Columbia University 
Press; 
Ormanidhi, O. and Stringa, O. (2008). Porter's Model of Generic Competitive 
Strategies. Business Economics, 43(3), pp.55-64; 
Percy, L. (1976). How Market Segmentation Guides Advertising Strategy. Journal of 
Advertising Research, 16(5), pp11-22; 
Porter, M. (1976). Interbrand Choice, Strategy and Bilateral Market Power. Cambridge, 
MA: Harvard University Press; 
Porter, M. E. (1980). Competitive Strategy. New York: Free Press; 
Porter, M. E. (1985). Competitive Advantage. New York: First Press; 
Rosen, S. (1978). Hedonic Prices and Implicit Markets: Product Differentiation in Pure 
Competition. Journal of Political Economy, 82(1), pp34-56; 
Rumelt, R. (1991). How much does industry matter. Strategic Management Journal, 12, 
pp167–185; 
Samuelson, P. (1976). Economics. New York: McGraw- Hill Book Company; 
Shaw, A. (1912). Some Problems in Market Distribution. Quarterly Journal of 
Economics, pp703-65; 
Weinstein, A. (2004). Handbook of Market Segmentation, New York: The Haworth 
Press; 
Wind, Y. (1978). Issues and Advances in Segmentation Research. Journal of Marketing 
Research, 15(3), pp317-337. 
Other references 
Accenture. (2013). Great Expectations: Why Pharma Companies Can’t Ignore Patient 
Services. Available at: https://www.accenture.com/us-en/insight-great-
expectations-why-pharma-companies-cant-ignore-patient-services-survey.aspx 
(Accessed on 3rd of November, 2015); 
46 
 
Capgemini Consulting & Health Prize. (2012). Estimated Annual Pharmaceutical 
Revenue Loss due to Non-adherence. Available at: https://www.adherence564.com/ 
(Accessed on 3rd of November, 2015); 
Centers for Disease Control and Prevention. (2011). Electronic Health Record Systems 
and Intent to Apply for Meaningful Use Incentives Among Office-based Physician 
Practices: United States, 2001–2011. Available at: 
http://www.cdc.gov/nchs/data/databriefs/DB79.pdf (Accessed on 3rd of November, 
2015);  
Centers for Disease Control and Prevention. (2013). FastStats: Death and Mortality. 
Available at: http://www.cdc.gov/nchs/fastats/deaths.htm (Accessed on 3rd of 
November, 2015); 
Deloitte. (2011). Survey of Health Care Consumers in the United States: Key Findings, 
Strategic Implications. Available at: 
http://www.statecoverage.org/files/Deloitte_US_CHS_2011ConsumerSurveyinUS_
062111.pdf (Accessed on 3rd of November, 2015); 
Deloitte. (2015). Connected health, how digital technology is transforming health and 
social car. Available at: http://www2.deloitte.com/uk/en/pages/life-sciences-and-
healthcare/articles/connected-health.html (Accessed on 3rd of October 2015); 
HalthAffairs. (2013). Affairs Policy Brief. Patient Engagement. Available at: 
https://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=86 (Accessed 
on 29th of September 2015); 
Linehealth. (2015). Patient Engagement: The key for sustainable healthcare. Available 
at: http://www.linehealth.com/ (Accessed on 29th of September 2015); 
Linehealth.com [online] Available at: http://blog.linehealth.com/2015/10/acos-whats-in-
for-patients/ (Accessed on 5th of November 2015); 
Linehealth.com [online] Available at: http://blog.linehealth.com/2015/11/5-digital-
health-trends-that-will-change-your-life/ (Accessed on 1st of December 2015); 
Linehealth.com [online] Available at: 
http://www.futuremarketinsights.com/reports/digital-healthcare-market (Accessed 
on 4th of November 2015) 
National Partnership for Women and Families. (2012). Making IT Meaningful – How 
Consumers Value and Trust Health IT. Available at: 
http://go.nationalpartnership.org/site/DocServer/HIT_Making_IT_Meaningful_Nati
onal_partnership_February_2.pdf (Accessed on 3rd of November, 2015);  
47 
 
New England Healthcare Institute. (2009). Thinking outside the pillbox. Available at: 
http://www.nehi.net/writable/publication_files/file/pa_issue_brief_final.pdf 
(Accessed on 3rd of November, 2015); 
NHS Commissioning Assembly. (2015). Technology Enabled Care Services Resource 
for Commissioners. Available at: https://www.england.nhs.uk/wp-
content/uploads/2015/04/TECS_FinalDraft_0901.pdf8 (Accessed on 3rd of October 
2015); 
Pew Research Center. (2013). Health Online 2013. Available at: 
http://www.pewinternet.org/2013/01/15/health-online-2013/ (Accessed on 3rd of 
November, 2015); 
PWC. (2008). Price of Excess: Identifying Waste in Healthcare. Available at: 
http://www.lifesaverapp.com/PDF/PDFsample5.pdf (Accessed on 3rd of 
November, 2015). 
 
